{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T10:13:45Z","timestamp":1778926425670,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.breast.2026.104785","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T08:17:00Z","timestamp":1775809020000},"page":"104785","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Antibody\u2013drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposure"],"prefix":"10.1016","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6085-1921","authenticated-orcid":false,"given":"Fatih","family":"Kemik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taha Koray","family":"\u015eahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakan","family":"\u00d6z\u00e7elik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet","family":"Sezer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcl","family":"Ba\u015faran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakine Damla","family":"A\u00e7\u0131kel Y\u00fcksel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gizem","family":"G\u00fcney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130brahim","family":"Y\u0131ld\u0131z","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d6zlem","family":"Er","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taner","family":"Korkmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sedat","family":"Biter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilek","family":"Erdem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salih","family":"T\u00fcnbekici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet","family":"Oru\u00e7","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Kaan","family":"G\u00fcren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerim","family":"Kaban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Musa Bar\u0131\u015f","family":"Aykan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d6mer Burak","family":"Ekinci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130lknur","family":"Delikta\u015f Onur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Kalem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O\u011fuz","family":"Altunok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Seyyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00fcnyamin","family":"G\u00fcney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orhun","family":"Akdo\u011fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melike","family":"Yaz\u0131c\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nargiz","family":"Majidova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sema","family":"T\u00fcrker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahad\u0131r","family":"K\u00f6yl\u00fc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cevat \u0130lteri\u015f","family":"K\u0131k\u0131l\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazan","family":"Demir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didem","family":"Tunal\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u015eahin","family":"La\u00e7in","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deniz","family":"Tural","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet","family":"Bilici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ertu\u011frul","family":"Bayram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erdem","family":"G\u00f6ker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Araz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130brahim Vedat","family":"Bayo\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nil","family":"Molinas Mandel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuri","family":"Karadurmu\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emir","family":"\u00c7elik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d6zt\u00fcrk","family":"Ate\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Havva","family":"Ye\u015fil \u00c7\u0131nk\u0131r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mesut","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u0131za Umar","family":"G\u00fcrsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozan","family":"Yaz\u0131c\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devrim","family":"\u00c7abuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deniz Can","family":"G\u00fcven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatih","family":"Sel\u00e7ukbiricik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sercan","family":"Aksoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u015eeyda","family":"G\u00fcnd\u00fcz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.breast.2026.104785_bib1","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.breast.2026.104785_bib2","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.breast.2026.104785_bib3","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.ymthe.2023.03.019","article-title":"Clinical perspective: antibody-drug conjugates for the treatment of HER2-positive breast cancer","volume":"31","author":"Najminejad","year":"2023","journal-title":"Mol Ther"},{"issue":"7","key":"10.1016\/j.breast.2026.104785_bib4","doi-asserted-by":"crossref","first-page":"6447","DOI":"10.3390\/curroncol30070474","article-title":"Antibody-drug conjugates in breast cancer: ascent to destiny and Beyond-A 2023 review","volume":"30","author":"Xiao","year":"2023","journal-title":"Curr Oncol"},{"issue":"2","key":"10.1016\/j.breast.2026.104785_bib5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/bcr3621","article-title":"Trastuzumab emtansine: mechanisms of action and drug resistance","volume":"16","author":"Barok","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"7","key":"10.1016\/j.breast.2026.104785_bib6","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci"},{"issue":"8","key":"10.1016\/j.breast.2026.104785_bib7","doi-asserted-by":"crossref","first-page":"e957","DOI":"10.1093\/oncolo\/oyae055","article-title":"Optimal sequential strategies for antibody-drug conjugate in metastatic breast cancer: evaluating efficacy and cross-resistance","volume":"29","author":"Chen","year":"2024","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.breast.2026.104785_bib8","doi-asserted-by":"crossref","first-page":"10211","DOI":"10.3390\/curroncol30120743","article-title":"Sequencing antibody drug conjugates in breast cancer: exploring future roles","volume":"30","author":"Fenton","year":"2023","journal-title":"Curr Oncol"},{"issue":"4","key":"10.1016\/j.breast.2026.104785_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2025.189369","article-title":"Sequencing of antibody drug conjugates in breast cancer: evidence gap and future directions","volume":"1880","author":"Pacholczak-Madej","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"2","key":"10.1016\/j.breast.2026.104785_bib10","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.apsb.2024.12.036","article-title":"Resistance to antibody-drug conjugates: a review","volume":"15","author":"Li","year":"2025","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"10.1016\/j.breast.2026.104785_bib11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13058-020-1252-7","article-title":"HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates","volume":"22","author":"Oca\u00f1a","year":"2020","journal-title":"Breast Cancer Res"},{"issue":"7","key":"10.1016\/j.breast.2026.104785_bib12","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-Positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"issue":"10390","key":"10.1016\/j.breast.2026.104785_bib13","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.breast.2026.104785_bib14","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial","volume":"30","author":"Cort\u00e9s","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.breast.2026.104785_bib15","article-title":"Real-world efficacy and safety of trastuzumab deruxtecan versus trastuzumab emtansine and tucatinib as second-line and third-line treatments for HER2-positive metastatic breast cancer: two target trial emulation studies","volume":"58","author":"Jourdain","year":"2025","journal-title":"Lancet Reg Health Eur"},{"issue":"20","key":"10.1016\/j.breast.2026.104785_bib16","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, A novel HER2-Targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.breast.2026.104785_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20051115","article-title":"HER2 directed antibody-drug-conjugates beyond T-DM1 in breast cancer","volume":"20","author":"Rinnerthaler","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.breast.2026.104785_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.breast.2026.104785_bib19","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","article-title":"Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer","volume":"122","author":"Hunter","year":"2020","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.breast.2026.104785_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041278","article-title":"Mechanisms of resistance to antibody-drug conjugates","volume":"15","author":"Abelman","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.breast.2026.104785_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24119674","article-title":"Mechanisms of resistance to antibody-drug conjugates","volume":"24","author":"Khoury","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.breast.2026.104785_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041130","article-title":"Resistance to antibody-drug conjugates targeting HER2 in breast cancer: molecular landscape and future challenges","volume":"15","author":"Guidi","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.breast.2026.104785_bib23","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/13543784.2020.1792443","article-title":"Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer","volume":"29","author":"Bartsch","year":"2020","journal-title":"Expet Opin Invest Drugs"},{"key":"10.1016\/j.breast.2026.104785_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104355","article-title":"Trastuzumab deruxtecan in breast cancer","volume":"198","author":"Mart\u00edn","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.breast.2026.104785_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/curroncol32010001","article-title":"The real-world clinical outcomes of heavily pretreated HER2+ and HER2-Low metastatic breast cancer patients treated with trastuzumab deruxtecan at a single centre","volume":"32","author":"Lazaratos","year":"2024","journal-title":"Curr Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:59:08Z","timestamp":1778925548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626000950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":25,"alternative-id":["S0960977626000950"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104785","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody\u2013drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposure","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104785","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104785"}}